1 / 60

Pediatrics Intern Seminar Childhood Nepbrotic Syndrome

Pediatrics Intern Seminar Childhood Nepbrotic Syndrome. Supervisors: 邱元佑 醫師 周信旭 醫師 Intern: 黃鈺堯. Patient Information. ● 黃啟展 ● 5 y/o male ● 5 y/o male ● G3P3NO, NSD, Full term ● BW: 21.1 kg (25~50%) Ht: 109.2 cm (75~90%). CC: Generalized edema for 2+ weeks. Brief History.

madelyn
Télécharger la présentation

Pediatrics Intern Seminar Childhood Nepbrotic Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatrics Intern SeminarChildhood Nepbrotic Syndrome Supervisors: 邱元佑 醫師 周信旭 醫師 Intern: 黃鈺堯

  2. Patient Information ●黃啟展 ●5 y/o male ●5 y/o male ●G3P3NO, NSD, Full term ●BW: 21.1 kg (25~50%) Ht: 109.2 cm (75~90%) CC: Generalized edema for 2+ weeks

  3. Brief History 92/12/08 Periorbital edema noted Generalized edema: face, limbs, scrotum, abdominal distension, oligouria W’t gain 20 kg → 22 kg (in days) 新樓 Hospital admission U/A: protein (+++), Alb: 1.7, cholesterol: 455 Impression: nephrotic syndrome Prednisolone + Albumin + Lasix CXR: R’t pleural effusion s/p thoracentesis 92/12/17 92/12/22 Transferred to 成醫 Ped ward by family’s request

  4. Urine Analysis ● SG: 1.015 ● BIL: - ● pH: 8.0 ● ERY: 10 ● LEU: 15 ● WBC: 1 - 3 ● NIT: - ● RBC: 1 - 2 ●PRO: > 300● Epith: 0 - 1 ● Glu: - ● Cast: - ● KET: - ● Crystal: - ● UBG: normal ● Bacteria: -

  5. Lab Results

  6. Lab Results ●CCr = 60.7 ml/min ●DPL = 11.9 g/24hrs ●Protein selective index = 0.056 < 0.1 (selevtive)

  7. Impression Neprotic syndrome, r/o steroid-resistance ●Prednisolone 2 mg/kg/day since 12/17 ●Albumin infusion x 6 courses

  8. DiscussionTreatments MethodsforChildhood Idiopathic Nephrotic Syndrome

  9. Clinical Characteristics ●Proteinuria > 40 mg/m2/hr (> 1 g/m2/24hrs) ●Hypoproteinemia Total protein < 5.5 g/dL; Alb < 2.5 g/dL ●Hyperlipidemia Cholesterol > 250 mg/dL ●Edema Periorbital,lower limbs,scrotum, generalized, pitting

  10. Pathophysiology

  11. Yet to be identified

  12. Pathophysiology ●Charge-selective barrier: Sialoprotein (-) / polyanionic glycosaminoglycans 69 ~ 150 kd restricted (i.e. Albumin) Loss of charge-selectivity → MCNS ●Size-selective barrier: Pore size in GMB > 150 kd restricted Loss of size-selectivity → MN

  13. Pathogenesis Uncertain ? Altered T-lymphocyte response ↓ Plasma factor ? ↓ Podocyte protein expression / function ↓ Glomerular capillary wall permeability Eddy A, et al., The Lancet, 2003

  14. Epidemiology ●Incidence: 2 ~ 3 per 100000 children ●Idiopathic nephrotic syndrome 90% Primary Nephritis (-) Primary extrarenal disease (-) Onset: 2 ~ 7 y/o Male: female (2:1) Three common histologies

  15. Histopathology 1. Minimal change nephroytic syndrome 85% Effacement of podocyte foot process 95% steroid-responsive 2. Focal segmental glomerulosclerosis 10% Juxtamedullary segmental scarring < 20% steroid-responsive Progressive, ESRD in 2 ~ 5 yrs 3. Membranous nephropathy 5% Increased mesangial cells / matrix 50% steroid-responsive

  16. Complications ●Infection: Spontaneous peritonitis 2~ 6% ●Thromboembolic diseases: risk of renal vein thrombosis

  17. Treatment Goals ●Non-specific: relieve S/S and secondary effects ●Specific: immunosuppressive therapy aimed at modulating the immune component of the disease ●Minimize complications and those of immunosuppressive drugs

  18. Non - Specific Tx Severe edema: Pleural effusion, ascites, scrotal edema ●Restricted water / salt (< 2 g/day) ●25% Albumin ivd (1 g/kg/day) ●Furosemide (1 ~ 2 mg/kg/4hrs) ●Monitor vol. depletion, e- disturbance, renal function

  19. Specific Tx 1. First-line: Oral corticosteroid 2. Second-line: Pulse methylpredisolone, Cyclophosphamide, Cyclosporin 3. Other immunosuppressive agents: Levamisole, Mycophenolate mofetil

  20. Oral Corticosteroid ●1 ~ 8 y/o: steroid-responsive MCNS 87% Try steroid therapy, hold renal biopsy ●Prednisolone (2 mg/kg/day; 60 mg/m2/day) po divided dose ●Proteinuria (1+ or less) for 4 consecutive days → “steroid-responsive” ●75% MCNS remission by 2 wks ●Prednisolone (60 mg/m2/day) qod for 4 wks

  21. Response to Steroid ●Steroid-resistant: Proteinuria (2+ or more) after 1 month of daily Prednisolone use Renal biopsy indicated ●Steroid-dependent: Relapse (proteinuria + edema) after switching to or terminating qod Prednisolone Tx ●Frequently relapsing: > 2 relapses in 6 months of initial response or > 4 relapses in any 12 months > 60% relapse in steroid-responsive cases

  22. Specific Tx 1. First-line: Oral corticosteroid 2. Second-line: Pulse methylpredisolone, Cyclophosphamide, Cyclosporin 3. Other immunosuppressive agents: Levamisole, Mycophenolate mofetil

  23. Pulse Methylprednisolone ●10 ~ 30 mg/kg bolus (Max: 1000 mg) iv qod x 6 doses Weekly pulse x 4 wks Every-other-week pulse x 4 doses ●Combination with oral corticosteroids, cyclophosphamide, or cyclosporin ●Remission rate: 64% (27/42) in steroid-resistant NS by 13.1±12.5 wks Kirpekar R, et al., Am J of Kidney Disease, 2002

  24. Adverse Effects of Steroid ●Buffalo hump / moon face ●Cutaneous striae ●Osteoporosis ●Hypertension ●Hyperglycemia ●Dyslipidemia ●Muscle weakness / fatigability ●Infection

  25. Cyclophosphamide (Endoxan) ●Alkylating agent used in C/T ●Interferes DNA cross-link covalently ●For steroid-resistant / dependent / frequently relapsing NS ●2 ~ 2.5 mg/kg/day for 8 ~ 12 wks ●Combined Prednisolone qod Tx ●Remission: 25 ~ 30% steroid-unresponsive p’ts Eddy A, et al., The Lancet, 2003

  26. Cyclophosphamide

  27. Side Effects of Cyclophosphamide ●Myelosuppression 32% ●Hemorrhagic cystitis 2.2% ●Bladder carcinoma ●Alopecia ●Gonadal toxicity: aspermia, amenorrhea Latta K, et al., Ped Nephrology, 2001

  28. Cyclosporin (Sandimmun) ●Immunosuppressant for transplantation ●Calcineurin inhibitor:↓IL-2,IL-3,IL-4, GM-CSF, TNF-α→ ↓T cell proliferation ●5 ~ 6 mg/kg/day + oral Prednisolone use ●Remission rate: 85% for steroid-responsive NS ●Side effects: gingival-hyperplasia, hirsutism, risk of cyclosporin-induced vasculopathy ●High nephrotoxicity: monitor renal function Eddy A, et al., The Lancet, 2003

  29. Cyclosporin

  30. Cyclosporine

  31. Specific Tx 1. First-line: Oral corticosteroid 2. Second-line: Pulse methylpredisolone, Cyclophosphamide, Cyclosporin 3. Other immunosuppressive agents: Levamisole, Mycophenolate mofetil

  32. Mycophenolate Mofetil(CellCept) ●Prevents allograft rejection ●Suppress de novo purine synthesis: ↓T cell / B cell / smooth muscle cell / fibroblast proliferation ●0.8 ~ 1.2 g/m2/day ●Leukopenia, GI discomfort, diarrhea, malaise, splenomegaly Barletta G, et al., Ped Nephrology, 2003

  33. MMF

  34. Levamisole ●Antihelmintic drug ●Immunomodulatory effect ? ●2.5 mg/kg qod, median 10 months ●↓relapse in frequently relapsing NS ●Risks of leukopenia, hepatoxity, agranulocytosis, vasculitis, encephalopathy Tenbrock K, et al., Ped Nephrology, 1998

  35. Conclusion ●Steroid-responsiveness: most important prognostic factor ●Oral Prednisolone first-line drug ●Alkylating agents, immuno uppressants for steroid-resistant/dependant, frequently relapsing nephrotic syndrome ●Levamisole, MMF require larger trials for efficacy

  36. References ● Nelson 17th edition ● Eddy A., et al. Nephrotic syndrome in childhood. The Lancet. 362:629-39, 2003. ● Habashy D., et al. Interventions for steroid-resistant NS. Ped Nephrology. 18:906-912, 2003. ● Schwarz A. New aspects of treatment of NS. J Am Soc Nephrol. 12: S44-47, 2001. ● Orth S., et al. The Nephrotic syndrome. NEJM. 338(17):1202-1211, 1998. ● Ponticelli C, et al. Other immunosuppressive agents for FSGS. Seminars in Nephrol. 23(2): 242-48, 2003. ● Tenbrock K., et al. Levamisole treatment in steroid sensitive and steroid resistant NS. Ped Nephrology. 12:459-462, 1998.

  37. References ● Day C., et al. MMF in the treatment of resistant idiopathic NS. Nephrol Dial Transplant. 17:2011-13, 2002. ● Barletta G., et al. Use of MMF in steroid dependant and resistant NS. Ped Nephrology. 18:833-837, 2003. ● Yorgin.P. Pulse methylprednisolone Tx of idiopathic steroid resistant NS. Ped Nephrology. 16:245-50, 2001. ● Kirpekar R., et al. Clinicopathgologic correlates predict... Am J of Kidney Diseases. 39(6):1143-1152, 2001.

  38. Thank you !

  39. Infections ●Spontaneous peritonitis 2~ 6% Sepsis, pneumonia, cellulitis, UTI Streptococcus pneumoniae, GNB common ●Protein deficiency, ↓immunoglobulin, ↓complement, ascites, immunosuppressive therapy

  40. Thromboembolic diseases ● Risk of renal vein thrombosis, pulmonary emboli, deep vein thrombosis ● Urine loss of antithrombin III Fibrinogen + clotting factors synthesis Platelet abnormalty: thrombocytosis, ↑aggregability Hyperviscosity Hyperlipidemia

  41. Corticosteroid Cyclosporine MMF Corticosteroid Cyclophosphamide

More Related